Suzhou Changzheng Cinkate Pharmaceutical Co., Ltd.

A single-center, randomized, open, single-dose, parallel trial design was used to compare the differences in the degree and rate of absorption of teriflunomide tablets (specification: 14 mg) provided by Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd. and teriflunomide tablets (specification: 14 mg, trade name: Aubagio®) licensed by Sanofi Aventis U.S. Inc. in healthy Chinese people under fasting and postprandial administration conditions, and to evaluate the safety of teriflunomide tablets provided by Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd.

Hydroxychloroquine sulfate tablets (specification: 200 mg) produced by Suzhou Changzheng Xinkai Pharmaceutical Co., Ltd. were used as the test preparation, and hydroxychloroquine sulfate tablets (specification: 0.2 g, trade name: PLAQUENIL®) certified by Aventis Pharma Limited were used as the reference preparation. A single-center, randomized, open, single-dose, single-period parallel trial design clinical study was conducted to evaluate the bioequivalence of the two preparations in humans under fasting and fed conditions.

1. To evaluate the safety of a single dose of tenofovir disoproxil fumarate in healthy subjects. 2. To evaluate the pharmacokinetic characteristics of a single dose of tenofovir disoproxil fumarate in healthy subjects.